Arvinas says first PROTAC protein degrader approval marks milestone for targeted protein degradation

Arvinas said the first approval of a PROTAC protein degrader marks a milestone for targeted protein degradation. The company is also advancing the platform with an HPK1 Phase 1/2 study and LRRK2 clinical data beyond oncology.

Detected & updated continuously · Source: Nebula